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Voltage-dependent anion channel-1 (VDAC1)3 is a highly
regulated ␤-barrel membrane protein that mediates transport
of ions and metabolites between the mitochondria and cytosol,
and is implicated in the control of mitochondrial respiration
and apoptosis (1, 2). Among the endogenous factors that alter
VDAC1 function, membrane lipids have been the subject of
several studies (3– 8), in part, because of the marked changes
that occur in mitochondrial lipid composition with apoptosis
(9) and neurodegenerative diseases (10). Sterols and anionic
phospholipids affect VDAC selectivity (6), voltage-dependent
gating (3, 7), and oligomerization (4). Furthermore, sterols copurify with VDAC from fungi (11) and bovine heart (12), and
are important for the functional reconstitution of purified
VDAC from eukaryotic expression systems (7).
Compared with ␣-helical integral membrane proteins
(IMPs), relatively few structural studies of ␤-barrel IMPs have
delineated binding sites for membrane lipids (13, 14), and this is
particularly true of cholesterol (15–17). Based on a VDAC
NMR study that reported chemical shifts at multiple residues in
the presence of cholesterol, five cholesterol-binding sites were
recently proposed by molecular modeling (5, 8). Experimental
evidence for the sites of cholesterol interaction in VDAC is
otherwise lacking.
One approach to map lipid-binding sites is photoaffinity
labeling, in which IMPs are covalently labeled with photoactivatable lipid analogues and the sites of interaction are identified
by bottom-up mass spectrometry (MS) (18, 19). In bottom-up
MS, the photolabeled IMP is digested into peptides, and the
photolabeled sites are determined by identifying and sequencing the associated peptide-ligand adducts. We have found this
process to be particularly challenging for sterol-based ligands
because the resulting peptide adducts have poor aqueous solubility and consistently undergo adduct loss with conventional
collision-induced dissociation fragmentation (20). To overcome these challenges, we have employed FLI-tag, a clickable
3

The abbreviations used are: VDAC1, voltage-dependent anion channel-1;
IMP, integral membrane protein; CHAPSO, 3-[(3-cholamidopropyl)dimethylammonio]-2-hydroxy-1-propanesulfonic acid; FA, formic acid; ACN,
acetonitrile.
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Voltage-dependent anion channel-1 (VDAC1) is a highly regulated ␤-barrel membrane protein that mediates transport of
ions and metabolites between the mitochondria and cytosol of
the cell. VDAC1 co-purifies with cholesterol and is functionally
regulated by cholesterol, among other endogenous lipids.
Molecular modeling studies based on NMR observations have
suggested five cholesterol-binding sites in VDAC1, but direct
experimental evidence for these sites is lacking. Here, to determine the sites of cholesterol binding, we photolabeled purified
mouse VDAC1 (mVDAC1) with photoactivatable cholesterol
analogues and analyzed the photolabeled sites with both topdown mass spectrometry (MS), and bottom-up MS paired with a
clickable, stable isotope-labeled tag, FLI-tag. Using cholesterol
analogues with a diazirine in either the 7 position of the steroid
ring (LKM38) or the aliphatic tail (KK174), we mapped a binding
pocket in mVDAC1 localized to Thr83 and Glu73, respectively.
When Glu73 was mutated to a glutamine, KK174 no longer photolabeled this residue, but instead labeled the nearby Tyr62
within this same binding pocket. The combination of analytical
strategies employed in this work permits detailed molecular
mapping of a cholesterol-binding site in a protein, including an
orientation of the sterol within the site. Our work raises the
interesting possibility that cholesterol-mediated regulation of
VDAC1 may be facilitated through a specific binding site at the
functionally important Glu73 residue.

Cholesterol-binding sites in VDAC
stable isotope-labeled tag, which enables peptide adducts to be
identified by an MS1 level search (20). We have also utilized
top-down MS to gain complementary information regarding
the efficiency, stoichiometry, and sites of photolabeling. Using
two analogues with a photoactivatable diazirine in different
positions, we have mapped a cholesterol binding pocket with a
preferred ligand orientation in mVDAC1.

LKM38 and KK174 define a cholesterol binding pocket in WT
mVDAC1 by photolabeling Thr83 and Glu73
To determine the exact residues photolabeled by LKM38 and
KK174, mVDAC1 was photolabeled with each reagent three
times at 30 and 100 M. The photolabeled proteins were derivatized with FLI-tag using copper-catalyzed cycloaddition. Bottom-up mass spectrometry was performed using an established
protocol (22), and peptide adducts were identified using an
automated pairs search followed by manual interpretation of
the ETD fragmentation spectra. All photolabeled residues are
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Results
Cholesterol analogues photolabel mVDAC1 with variable
efficiency and a stoichiometry of one
To determine cholesterol-binding sites in VDAC1, we photolabeled WT mouse VDAC1 (mVDAC1) with two cholesterol
analogues that have a photoactive diazirine in either the 7-position (LKM38) (21) or the aliphatic tail (KK174) (see Fig. 1A for
structures and supplemental materials for KK174 synthesis).
These reagents were designed to permit mapping of cholesterol
binding pockets by placing the diazirine in different positions.
They also contain an alkyne allowing for the attachment of FLItag to facilitate identification of peptide-steroid adducts (20).
Top-down MS of photolabeled mVDAC1 was first performed
to characterize the efficiency and stoichiometry of labeling. The
masses of mVDAC1 photolabeled by LKM38 and KK174 are
listed in Table 1. First, mVDAC1 was photolabeled three times
with 100 M of cholesterol analogue added each time. LKM38,
which has the diazirine in the 7-position, photolabeled
mVDAC1 with an efficiency of only ⬃38% (Fig. 1A). KK174,
which has the diazirine in the aliphatic tail, photolabeled
mVDAC1 with 100% efficiency; the absence of a feature corresponding to mVDAC1 photolabeled with two ligands is consistent with a stoichiometry of one (Fig. 1A). HCD fragmentation
of intact mVDAC1 gives limited sequence coverage, and therefore top-down mass spectrometry can only localize photo-incorporation of the ligands to a general region within the
protein. Fragmentation of photolabeled mVDAC1 showed a
series of b ions that localize the photolabeled site to a region
encompassing residues 44 –120 for LKM38, and residues
44 –128 for KK174 (Fig. 1B). The variable photolabeling efficiencies of these two analogues under exhaustive photolabeling conditions suggest that they may photolabel different
residues within this region. We also tested KK174 photolabeling of mVDAC1 at different concentrations, which demonstrated concentration-dependent labeling that saturates
above 100 M (Fig. 2, A and B). The apparent EC50 of photolabeling is 15.3 M (Fig. 2B), which is a function of both
binding and photochemical efficiency and thus not indicative of binding affinity.

Figure 1. Top-down MS of mVDAC1 photolabeled with cholesterol analogues. A, chemical structures of cholesterol analogues, and associated
deconvoluted spectra of mVDAC1 photolabeled with LKM38 and KK174. For
LKM38, two peaks in the deconvoluted spectrum represent unlabeled and
singly labeled mVDAC1 at 32,157 and 32,553 Da, respectively. For KK174, the
one peak represents singly labeled mVDAC1 at 32,537 Da. B, HCD fragment
ion assignments obtained by isolating the LKM38- and KK174-photolabeled
species, respectively. Amino acids are numbered to exclude the first 12 residues in the N terminus that comprise the affinity tag. The gray lines represent
b and y ions that do not contain a ligand adduct. The black lines represent b
ions that do contain a ligand adduct and were identified by searching the
fragmentation data against a database in which the ligand mass was added to
the N-terminal methionine. The absence of red lines indicates an absence of y
ions identified by searching against a database in which the ligand mass was
added to the C-terminal alanine.

listed in Table 2. We first examined KK174. A search of the MS1
data identified multiple paired features consistent with peptide-KK174 adducts (supplemental Table S1). Analysis of the
ETD fragmentation spectra for each of these paired features
localized the site of KK174 insertion to Glu73 (Fig. 3, A and B,
J. Biol. Chem. (2017) 292(22) 9294 –9304
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Table 1
Masses of photolabeled mVDAC1 acquired on the Elite LTQ
Average mass

Theoretical mass

32553.0
32537.0
32550.0
32537.0
32493.0
32477.4

32550.38
32534.35
32549.39
32533.36
32492.34
32476.31

100 M ⴛ 3

Mass accuracy

Da

WT LKM38
WT KK174
E73Q LKM38
E73Q KK174
E73A LKM38
E73A KK174

Table 2
Summary of KK174 and LKM38 photolabeling sites in mVDAC1

ppm

81
82
19
112
20
34

WT
E73Q

KK174
LKM38
KK174
LKM38

73

Glu
Thr83
Tyr62, Lys110, Tyr173, Asp230, Ala283
None identified

30 M
73

Glu
None identified
Lys110
None identified

Competitive inhibition of cholesterol photolabeling in
mVDAC1
To confirm that the photolabeled site is an actual cholesterol-binding site, we photolabeled mVDAC1 with 1 M KK174
or LKM38 in the presence of excess cholesterol. Photolabeled
mVDAC1 was detected by coupling the photolabeled protein to
TAMRA using click chemistry, separating the protein by SDSPAGE, and visualizing with fluorescent imaging. Labeling by
KK174 was inhibited by 30 M cholesterol, and labeling by
LKM38 showed a trend toward inhibition that was not statistically significant (Fig. 4, A and B). Competitive inhibition of
photolabeling by cholesterol for KK174 is consistent with the
conclusion that cholesterol binds to the site photolabeled by
this analogue.
Cholesterol analogues photolabel E73 mutants: top-down
analysis

Figure 2. Concentration-dependent photolabeling of mVDAC1 by KK174
demonstrates saturation and a stoichiometry of one. A, deconvoluted
spectra of mVDAC1 photolabeled with KK174 at 0, 10, 30, and 200 M. The
theoretical average masses of unlabeled mVDAC1, singly labeled mVDAC1,
and doubly labeled mVDAC1 are 32,154, 32,534, and 32,914 Da, respectively.
B, scatter plot of the photolabeling efficiency of mVDAC1 by KK174. Data are
fit with a four-parameter logistic equation, which yields an apparent EC50 of
15.3 M and Hill slope of 1.6.

9296 J. Biol. Chem. (2017) 292(22) 9294 –9304

Top-down analysis of photolabeled E73Q and E73A mVDAC1
revealed reduced labeling efficiency in the mutants for both
LKM38 (8% for E73Q and 13% for E73A) and KK174 (21% for
E73Q and 10% for E73A) (Fig. 5, A and B). Moreover, top-down
analysis with HCD fragmentation for both mutants identified
photolabeled sites in two regions, compared with just one for
WT (Fig. 5, C and D). LKM38 photolabeling of E73Q showed a
series of b ions localizing a site or sites from residues 44 –135, as
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supplemental Table S1). No other photolabeled residues were
identified consistent with a stoichiometry of one (supplemental
Table S1).
For LKM38 we identified two paired features consistent with
peptide-LKM38 adducts (supplemental Table S1). Both features localized the site of LKM38 insertion to Thr83 (Fig. 3, C
and D). Interestingly, Thr83 is directly adjacent to Glu73 in the
neighboring ␤-strand based on the mVDAC1 crystal structure
(23). Despite being in such close proximity to Glu73, LKM38
selectively photolabels Thr83. No peptide adducts with Glu73
labeling were observed in the LKM38 sample (supplemental
Table S1). To further explore whether these two residues form
a single cholesterol-binding site, Autodock simulations were
performed using cholesterol and the mVDAC1 structure (23,
24), with docking constrained to a 30 ⫻ 30-Å area centered on
Glu73. After clustering 1000 poses, the two most populated
clusters show cholesterol bound to a groove formed by Phe71,
Glu73, Thr83, and Ile85 as well as Tyr62 and Ser101 on either end
of the cholesterol molecule (Fig. 3E). The pose that most closely
agrees with the experimental data shows, quite remarkably, that
the end of the cholesterol aliphatic tail is 3.5 Å from Glu73 and
position 7 of the steroid ring is 2.5 Å from Thr83 (Fig. 3F). In
summary, using two cholesterol analogues with the photoactivatable diazirine in different positions, we have precisely
mapped a cholesterol-binding site in mVDAC1.

Cholesterol-binding sites in VDAC

well as a series of y ions localizing a site or sites from residues
133–209 (Fig. 5C). A similar pattern of altered HCD fragmentation was observed for KK174 labeling of E73Q (Fig. 5C) as well
as KK174 and LKM38 photolabeling of E73A (Fig. 5D). This
suggests that there is at least one additional site of cholesterol
labeling in the E73Q and E73A mutants compared with WT.
KK174 photolabels multiple residues in the E73Q mutant
including Tyr62 in the cholesterol binding pocket
Bottom-up analysis was performed for LKM38 and KK174
photolabeling of E73Q. For KK174, we identified multiple peptide adducts (supplemental Table S1). Three peptide-KK174
adducts were identified in which KK174 insertion was localized
to Tyr62 (Fig. 6, A and B). Interestingly, this residue is adjacent
to Glu73 in the mVDAC1 structure. Based on the modeled cho-

lesterol binding pocket, Tyr62 is 6.0 Å away from the flexible
aliphatic tail of cholesterol using the most prominent docking
pose (Fig. 6C). Thus, it appears that cholesterol still binds to a
groove (Fig. 6D) defined by Thr83, Gln73, and Tyr62 in the E73Q
mutant. However, most likely because tyrosine is more nucleophilic than glutamine, Tyr62 becomes the preferred target for
KK174 over Gln73. In addition to Tyr62, four other residues
were photolabeled by KK174 in the E73Q mutant: Lys110,
Tyr173, Asp230, and Ala283 (Fig. 7, supplemental Table S1).
KK174 labeling of the lysine residue, Lys110 (Fig. 7, A, B, and E),
is observed with both exhaustive photolabeling (100 M ⫻ 3)
and photolabeling at 30 M (supplemental Table S1). Labeling
of Tyr173 (Fig. 7, C and D) is consistent with top-down fragmentation data where photolabeled sites in E73Q were localized to
two regions including a C-terminal region, which was not
J. Biol. Chem. (2017) 292(22) 9294 –9304
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Figure 3. Bottom-up MS of mVDAC1 photolabeled with cholesterol analogues maps a cholesterol-binding site. A, representative MS1 doublet corresponding to the peptide GLTFTEKW labeled with KK174 (z ⫽ 4) and coupled to light and heavy FLI-tag. B, fragmentation (ETD) spectra corresponding to the
heavy feature in A. The site defining ions localize KK174 labeling to Glu73. C, a representative MS1 doublet corresponding to the peptide NTDNTLGTEITVEDQLARGL labeled with LKM38 (z ⫽ 4) and coupled to light and heavy FLI-tag. D, fragmentation (ETD) spectra corresponding to the light feature in C. Site
defining ions localize LKM38 labeling to Thr83. E, a cholesterol-binding pose from AutoDock bound by Tyr62, Phe71, Glu73, Thr83, Ile85, and Ser101. F, same
cholesterol binding pose as in E showing the aliphatic tail 3.5 Å from Glu73 and the 7 position 2.5 Å from Thr83, consistent with KK174 and LKM38 labeling of
these residues.

Cholesterol-binding sites in VDAC

detected in WT. Tyr173 is in close proximity to one of the sites
previously identified by molecular modeling (25). We replicated this result by performing an Autodock simulation that
searched the entire mVDAC1 structure, and identified a highly
populated cluster within this site. The average pose of cholesterol in this site shows the flexible aliphatic tail bound by Trp149
and Val171, but also in close proximity to Tyr173 (⬃8 Å) (Fig.
7F). Due to the low efficiency of LKM38 photolabeling in the
mutants, we were unable to identify LKM38-labeled sites in
E73Q by bottom-up mass spectrometry.
Mixing experiment to test for the formation of a long-lived
reactive intermediate
Aliphatic diazirines are capable of forming short-lived reactive carbenes and also of rearranging to form long-lived intermediates, such as a diazo compound (26). Formation of longlived intermediates increase the likelihood of ligand diffusion
and labeling of residues remote from the binding site. To test if
KK174 and LKM38 form long-lived reactive intermediates, we
irradiated 30 M of each reagent for 1 min prior to immediate
mixing with mVDAC1. We then clicked the samples to
TAMRA, separated the protein via SDS-PAGE, and visualized
via fluorescent imaging. Irradiating LKM38 prior to mixing
with mVDAC1 does not result in significant labeling, in contrast to KK174 which does (Fig. 8). This indicates that activated
KK174 but not LKM38 forms a long-lived intermediate with a
lifetime of seconds to minutes.

9298 J. Biol. Chem. (2017) 292(22) 9294 –9304

Discussion
Cholesterol is abundant and highly regulated in membranes,
including the outer mitochondrial membrane where VDAC is
the most abundant integral membrane protein (27, 28). The
fact that multiple cholesterol molecules remain bound to
VDAC after detergent solubilization and purification indicates
a specific interaction (11, 12), which is likely mediating effects
such as the modulation of VDAC gating (6, 11). However, the
structural basis of cholesterol interaction with VDAC has not
been well characterized. We utilized a photoaffinity labeling
approach combined with top-down and bottom-up MS to identify and map cholesterol-binding sites in mVDAC1. Photolabeling efficiency and fragmentation patterns provided by topdown MS complemented our residue level site identification by
bottom-up MS. Furthermore, derivatization with FLI-tag and
subsequent ETD fragmentation enabled detection of sterolbased peptide adducts and site-defining ions, which are otherwise difficult to identify due to collision cell adduct loss (20).
Four key aspects of cholesterol photolabeling in WT
mVDAC1 support the photolabeled residues being a specific
cholesterol-binding site. First, residues photolabeled by two
cholesterol analogues, LKM38 with the diazirine on the 7-position of the steroid ring, and KK174 with the diazirine on the
aliphatic tail, map a single binding pocket in WT mVDAC1.
Glu73 and Thr83, which are photolabeled by KK174 and
LKM38, respectively, are separated by only 6 Å in the mVDAC1
crystal structure. KK174 photolabels Glu73 with high efficiency
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Figure 4. Competitive inhibition of LKM38 and KK174 photolabeling of mVDAC1 by cholesterol. SDS-PAGE of WT mVDAC1 photolabeled for 1 min with
1 M LKM38 (A) or KK174 (B) in the absence and presence of 10 or 30 M cholesterol. The gel bands on the left show fluorescence signal with TAMRA or SYPRO
Ruby. The scatter plots on the right show densitometry measurements of TAMRA signal from three separate experiments. Error bars indicate S.D. * indicates p ⬍
0.05 and ** p ⬍ 0.01 based on an analysis of variance with Tukey HSD test.

Cholesterol-binding sites in VDAC

consistent with the photochemical preference of aliphatic
diazirines for nucleophilic acidic amino acids (26). The fact that
LKM38 labels Thr83, rather than the nearby, more nucleophilic
glutamate residue, indicates that cholesterol is significantly
constrained within this binding pocket.
A second aspect of cholesterol photolabeling that argues for
specific binding is the photolabeling of E73Q mVDAC1. The
conservative E73Q mutation abolishes KK174 photolabeling of
residue 73, without disrupting binding at this site because
KK174 then photolabels the nearby residue, Tyr62. With the
diazirine at the end of a flexible aliphatic tail, we predict that
KK174 photolabels Tyr62 within the constraints of the same
binding pocket defined in WT mVDAC1. The orientation of
cholesterol within this binding pocket agrees remarkably well
with results from docking simulations.

Third, KK174 photolabels mVDAC1 with a stoichiometry
of one at concentrations well above saturation (i.e. 100%
mVDAC1 is photolabeled), indicating that this singular photolabeled site is highly specific. Even at concentrations greater
than three times needed to saturate labeling at Glu73, a
mVDAC1 species labeled with two KK174 is not observed by
top-down MS. This finding is particularly remarkable in light of
the fact that KK174 forms a long-lived reactive intermediate,
which may be prone to diffuse and nonspecifically photolabel
other sites.
Last, inhibition of KK174 photolabeling in WT mVDAC1 by
excess cholesterol also argues for Glu73 being a cholesterolbinding site. Cholesterol inhibition of LKM38 photolabeling
was modest and not statistically significant. We have found that
competitive inhibition of ligand photolabeling also cannot be
J. Biol. Chem. (2017) 292(22) 9294 –9304
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Figure 5. Top-down MS of E73Q and E73A mVDAC1 photolabeled with cholesterol analogues. A, deconvoluted spectra of E73Q mVDAC1 photolabeled
with LKM38 and KK174. For LKM38, the two peaks represent unlabeled and singly labeled E73Q at 32,153 and 32,550 Da, respectively. For KK174, the two peaks
represent unlabeled and singly labeled E73Q at 32,153 and 32,493 Da, respectively. B, same as A for E73A mVDAC1. For LKM38, the two peaks represent
unlabeled and singly labeled E73A at 32,097 and 32,493 Da, respectively. For KK174, the two peaks represent unlabeled and singly labeled E73A at 32,097 and
32,477 Da, respectively. C, HCD fragment ion assignments obtained by isolating the LKM38- and KK174-E73Q photolabeled species, respectively. The gray lines
represent b and y ions that do not contain a ligand adduct. The black lines represent b ions that contain ligand adduct identified by searching against a database
in which the ligand mass was added to the N-terminal methionine. The red lines represent y ions that contain ligand adduct identified by searching against a
database in which the ligand mass was added to the C-terminal alanine. D, same as C for E73A mVDAC1.

Cholesterol-binding sites in VDAC

demonstrated for known ligand-receptor interactions such as
the GABA receptor and neurosteroids (19). We suspect the
reasons competition is difficult to demonstrate or replicate in
certain cases include the low affinity of ligands such as neurosteroids or cholesterol, the irreversible nature of photolabeling
combined with relatively long photolabeling times, and the possibility that photoactivatable analogues have different binding
affinities than the ligands themselves (29). Thus, whereas the
presence of inhibition by cholesterol of KK174 photolabeling
confirms that Glu73 is a cholesterol-binding site, the lack of
significant inhibition in the case of LKM38 does not lead to the
opposite conclusion.
Glu73 is a uniquely positioned, charged amino acid in the
transmembrane region of ␤-strand 4 that faces out into the
membrane. Interestingly, this residue is an important determinant of VDAC1 channel activity and is implicated in hexokinase
or ruthenium red-mediated inhibition of apoptosis (30). The
presence of a cholesterol-binding site at Glu73 raises the interesting hypothesis that this site is mediating the effects of cholesterol on VDAC function (6, 11). Cholesterol binding at Glu73
may also be mediating interactions with other proteins, because
Glu73 is critical for the interaction of hexokinase-I with VDAC
(30) and potentially dimerization of VDAC itself (23).
We also observed that cholesterol analogues photolabel
additional sites in E73Q compared with WT mVDAC1. Evidence for specific binding of cholesterol to these residues is
limited. One site, Tyr173, is near one of five binding sites previously predicted by molecular modeling (8). Unfortunately, low
photolabeling efficiency prevented the mapping of these sites
using LKM38 in the E73Q mutant. Given the finding that
KK174 can form a long-lived reactive intermediate, we cannot

9300 J. Biol. Chem. (2017) 292(22) 9294 –9304

exclude the possibility that labeling of these residues is nonspecific, resulting from diffusion of a long-lived reactive intermediate. This is especially likely for Asp230, which is located in a
soluble loop of the mVDAC1 protein.
We also cannot exclude the possibility that there are cholesterol sites not identified by our photolabeling experiments. Five
cholesterol molecules were estimated to bind VDAC when
purified from bovine heart (12). A previous molecular modeling
study defined five cholesterol-binding sites based on the
mVDAC1 structure and chemical shift data from an NMR
study (5, 8). We recognize that our cholesterol analogues
mainly photolabel nucleophilic residues and that the sites proposed in the computation study are predominantly composed
of aliphatic amino acids and few hydrophilic residues. Thus,
these other putative cholesterol-binding sites might not have
been identified due to limitations in our photolabeling reagents.
Alternatively, molecular docking to a static mVDAC1 structure
or NMR data obtained in detergent micelles may not recapitulate the dynamic state of mVDAC1 in a membrane environment, where the cholesterol binding pocket we identified at
Glu73 is predicted to have significant flexibility (31). Indeed,
photoaffinity labeling provides an advantage over studies based
on static crystal structures in that multiple protein conformations are likely sampled in a lipid environment.
In conclusion, we have identified a specific cholesterol-binding site in mVDAC1 using photoaffinity labeling. Using two
cholesterol analogues with the diazirine in different positions,
we have precisely mapped this site with photolabeling of Glu73,
Thr83, and Tyr62. This work raises the interesting hypothesis
that cholesterol regulation of VDAC1 may be mediated
through a specific binding site at this functionally important
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Figure 6. Photolabeling a third residue, Tyr62, in the cholesterol binding pocket in E73Q mVDAC1. A, an MS1 doublet corresponding to the peptide
TSSGSANTETTKVNGSLETKYRWTEY from E73Q mVDAC1 photolabeled with KK174 (z ⫽ 5) and coupled to light and heavy FLI-tag. B, fragmentation (ETD) spectra
corresponding to the feature in A. Site defining ions localize KK174 photolabeling to Tyr62. C, the same cholesterol binding pose as in Fig. 2E showing Tyr62,
Glu73, and Thr83. D, space filling view of the binding pocket mapped by KK174 and LKM38.

Cholesterol-binding sites in VDAC

Figure 8. Formation of a long-lived reactive intermediate for KK174 but not LKM38. SDS-PAGE of mVDAC1 photolabeled with 30 M KK174 and LKM38.
KK174 and LKM38 were UV irradiated for 1 min in the presence of mVDAC1 (UV Ligand ⫹ Protein), or in the absence of mVDAC1 followed by immediate mixing
with mVDAC1 (UV Ligand). The gel bands show fluorescence signal with TAMRA (left) or SYPRO Ruby (right).

J. Biol. Chem. (2017) 292(22) 9294 –9304
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Figure 7. Additional sites of KK174 photolabeling in E73Q mVDAC1. A, an MS1 doublet corresponding to the peptide TGKKNAKIKTGY labeled with KK174
(z ⫽ 4) and coupled to light and heavy FLI-tag. B, fragmentation (ETD) spectra corresponding to the heavy feature in A. Site defining ions localize KK174 labeling
to Lys110. C, an MS1 doublet corresponding to the peptide AVGYKTDEF labeled with KK174 (z ⫽ 4) and coupled to light and heavy FLI-tag. D, fragmentation
(ETD) spectra corresponding to the light feature in C. Site defining ions localize KK174 labeling to Tyr173. E, mVDAC1 crystal structure (PDB code 3emn)
highlighting the photolabeled residue Lys110. F, a cholesterol binding pose from Autodock located within a previously identified cholesterol binding pocket (8)
formed by Val171, Ala151, Leu144, Ile123, Tyr146, and Trp149. The aliphatic tail of cholesterol in this pose is near Tyr173, consistent with KK174 labeling of this residue
in E73Q mVDAC1.
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residue. To our knowledge, this is the first time a sterol-binding
site has been defined with photolabeling reagents in such
molecular detail. This approach could be applied to precisely
map sterol-binding sites in other integral membrane proteins.

Experimental procedures
Expression and purification of mVDAC1 from Escherichia coli
Protein expression and purification were performed as
described previously (23). In short, mVDAC1 carrying a His6
tag was expressed using M15 E. coli cells. Inclusion bodies were
isolated, solubilized, and mVDAC1 was purified on a Talon
affinity column. The protein was then refolded and a size exclusion chromatography step allowed isolation of a homogeneous
population.
Top-down MS of photolabeled mVDAC1
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max ⫺ min
x ⫺Hill slope
1⫹
EC50

冉 冊

(Eq. 1)

where max is maximum labeling efficiency set at 100%, min is
minimum labeling efficiency set at 0%.
Click chemistry and endoproteolytic digestion of photolabeled
mVDAC1
Aliquots of photolabeled VDAC were diluted to 100 l and
SDS was added to 1%. FLI-tag was covalently attached at sites of
ligand incorporation via copper-catalyzed cyclo-addition
(click chemistry) as previously described (40). Briefly, 2 mM
C6H7NaO6, 0.1 mM Tris(benzyltriazolylmethyl)amine, and 1
mM CuSO4 were added and the reaction was initiated by 0.5 mM
FLI-tag (in a 1:1 light to heavy ratio). The reaction was kept at
room temperature overnight. As previously described (22), the
protein was precipitated with a 2D SDS clean-up kit (GE
Healthcare) and delipidated with 5% RapigestTM (in 20 l of
100 mM Tris, pH 8.0, 8 M urea) at 37 °C for 1 h. The protein was
precipitated a second time and resuspended in 8 M urea, 0.2%
RapigestTM. The protein was then reduced with 5 mM triscarboxyethylphosphine, alkylated with 5 mM idoacetamide, and
alkylation was quenched with 5 mM DTT. The protein was
digested overnight at 37 °C with 2 g of endoprotease LysC, and
then diluted to 1 M urea with 100 mM Tris, pH 8.0, ⫹ 10 mM
CaCl2 and digested with 2 g of chymotrypsin for 3 or 6 h.
Digestions were stopped with 1% formic acid (FA) and incubated at 37 °C for 30 min before peptides were sequentially
extracted with C4 and C18 stage tips. Peptides were eluted from
stage tips with 10% ACN, 1% FA, dried via vacuum centrifugation, resuspended in 10% ACN, 1% FA, and analyzed by
LC/MS/MS on an Orbitrap Elite mass spectrometer.
Liquid chromatography and high resolution tandem mass
spectrometry
Samples were analyzed as previously described (20). Samples
were separated on a home packed C18 column (15 cm ⫻ 75 M ⫻
200 Å) and introduced to the mass spectrometer with a nanospray source. Samples were separated on a 102-min gradient (5
min hold at 10% ACN, 1% FA, increase to 90% ACN, 1% FA over
85 min, hold at 90% ACN, 1% FA, flow rate ⫽ 800 nl/min).
Survey scans were collected in the Orbitrap (res 60,000) and
MS2 (MS/MS) scans were acquired using data-dependent
acquisition of the 20 most abundant features. MS2 spectra were
acquired using either collision-induced dissociation (normalized collision energy ⫽ 35) or ETD (100 ms activation time).
Dynamic exclusion limited MS2 collection of a given m/z to one
event every 15 s. ETD MS2 collection was limited to features
with z ⬎ ⫽ 3.
MS1-based pair search
Bottom-up spectra were analyzed via a pair search as previously described (20). Briefly, .raw data were converted to .mzml
via MSConvert. OpenMS featurefinder multiplex tool was
used to identify pairs separated by 10.008 Da and results
were processed in Knime to exclude pairs with integral of
intensity differences greater than 50%. The feature list cre-
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Reconstitution of mVDAC1, photolabeling, and top-down
MS was performed as previously described (32–35). 120 g of
WT or mutant mVDAC1 was reconstituted by adding a 35%
solution of L-␣ -dimyristoylphosphatidylcholine/CHAPSO
bicelles in a 4:1 volume ratio of protein to bicelles and incubating on ice for 30 min. Samples were then diluted to 100 l with
20 mM Tris buffer, pH 8, and photolabeled with cholesterol
analogues at different concentrations via irradiation in a quartz
cuvette with ⬎320 nm UV light as previously described (35). 30
g were removed for bottom-up analysis. The samples were
then reduced with 250 mM DTT as previously described (36).
Briefly, methanol, chloroform, and water in approximately
equal volumes were added to the sample, vortexed, and centrifuged. The upper phase was removed and methanol and water
were added and centrifuged three more times to further wash
the sample. After the final wash, the precipitated protein was
pelleted, reconstituted in 2 l of 90% formic acid (37), and then
diluted in 120 l of chloroform/methanol/water (4:4:1). Topdown MS analysis was performed by direct injection of this
sample at 3 l/min using a Max Ion API source with a HESI-II
probe into an Orbitrap Elite MS (Thermo Scientific, Waltham,
MA). Full spectra of intact photolabeled mVDAC1 were
acquired on the LTQ using a spray voltage of 4 kV, capillary
temperature of 320 °C, in source dissociation voltage of 30 V,
and otherwise standard tune parameters. The HCD/C-trap ⌬P
was adjusted to between 0.05 and 0.1 to optimize Orbitrap analysis of fragmentation spectra. HCD fragmentation spectra were
acquired at 60,000 resolution, with an AGC target of 5 ⫻ 105,
normalized energy of 10, activation time of 0.1 ms, and 4 m/z
isolation window of the 31⫹ charge state. Deconvolution of full
spectra from the LTQ was performed using MagTran (38).
MASH was used for deconvolution of isotopically-resolved
spectra to obtain monoisotopic masses, and to analyze topdown HCD fragmentation data (39). Fragment ions were
searched using a mass accuracy of 1.1 Da to account for the “␦ 1
Da” error (33). Fragment ions containing ligand were identified
by adding the monoisotopic mass of the ligand to the N-terminal or C-terminal amino acids and searching for fragment ions
plus ligand. Each identified fragment ion was manually verified
and accepted if within 10 ppm. Fit of the concentration dependence of KK174 photolabeling efficiency was performed in
Excel using a standard logistic binding equation,

y ⫽ min ⫹
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ated in Knime was exported to Excel and z ⬎ ⫽ 2 pairs were
manually analyzed in Xcalibur for correct charge state and
isotope distribution.
MS2-based software searches
ETD fragmentation spectra were searched against a database
containing the mVDAC1 sequence (UniProtKB code Q60932)
modified with a His6 tag and filtered at a 1% false discovery rate
using PEAKS 8.0 (Bioinformatics Solution Inc.). Met oxidation
and Cys carbamidomethylation were included in each sample
as variable modifications. Customized modifications were created for the add weight of KK174 ⫹ FLI-tag (light m/z ⫽
680.474, heavy m/z ⫽ 690.482) and LKM38 ⫹ FLI-tag (light
m/z ⫽ 696.505, heavy m/z ⫽ 706.513).
Gel-based competition assay

Mixing experiment
30 M KK174 and LKM38 were irradiated with UV for 1 min
in the presence or absence of mVDAC1. Reagent irradiated in
the absence of mVDAC1 was immediately mixed with protein following UV irradiation. All samples were then incubated in the dark for 5 min before being denatured with SDS
and clicked to TAMRA azide. SDS-PAGE, TAMRA fluorescence imaging, and SYPRO Ruby imaging were performed as
described above.
Autodock analysis of the cholesterol-binding site
Cholesterol binding poses were obtained with AutoDock 4.2
(24). Docking was performed with the mVDAC1 crystal structure (PDB code 3emn) prepared in AutoDock Tools by deleting
waters, adding hydrogen, computing Gasteiger charges, and
merging non-polar hydrogens. The cholesterol ligand was prepared by converting an sdf file from Pubchem into a pdb file
using Open Babel (41), and partial charges and torsion angles
were calculated using PRODRG set for reduced charges and
energy minimization (42). The AutoDock grid box was chosen
to be a 30 ⫻ 30 ⫻ 30-Å space entered on Glu73 with 0.3-Å
spacing. Alternatively, docking was also performed with a grid
that encompassed the entire protein with 1.0-Å spacing. Docking was performed using the genetic algorithm, 1000 runs, and
otherwise default parameters. Clustering of the resulting 1000
poses at 2-Å root mean square deviation yielded multiple clusters, which were considered for comparison with photolabeled
data.
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